Genmab announces favorable topline results from phase 2 clinical trial of tisotumab vedotin

Reg-genmab announces very favorable topline results from phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic cervical cancer.genmab and seattle genetics plan to discuss results with u.s. food and drug administration.tisotumab vedotin is being developed in collaboration with seattle genetics.
SGEN Ratings Summary
SGEN Quant Ranking